Our Pricing

Understanding the Difference Between Ozempic and Wegovy in the UK

Many UK patients searching for an ozempic vs wegovy uk comparison discover that whilst both medications contain the same active ingredient—semaglutide—they differ significantly in their licensed indications, dosing schedules, and pricing. At Cured Pharmacy, our UK-registered clinical team helps patients understand which semaglutide treatment is appropriate for their needs, with Wegovy available from £79.00 following a free online consultation.

Are Ozempic and Wegovy Actually the Same Medication?

Both Ozempic and Wegovy contain semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally developed to improve glycaemic control in type 2 diabetes [1]. The crucial difference lies in their MHRA licensing: Ozempic is licensed exclusively for type 2 diabetes management, whilst Wegovy is specifically licensed for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [2].

Using Ozempic for weight loss constitutes off-label prescribing in the UK. Whilst some private clinics may offer this, Wegovy remains the only semaglutide formulation with regulatory approval for obesity treatment. This distinction affects not only legal prescribing practices but also insurance coverage, patient safety monitoring, and access to appropriate clinical support.

The molecular structure of semaglutide is identical in both medications, but Wegovy is formulated to reach higher maintenance doses—up to 2.4mg weekly compared to Ozempic's maximum 1mg dose for diabetes [2]. This higher dosing is what enables the superior weight loss outcomes observed in clinical trials.

Clinical Evidence: Weight Loss Outcomes with Semaglutide

The landmark STEP clinical trial programme established Wegovy's efficacy for weight management. In the STEP 1 trial, participants using semaglutide 2.4mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [2]. More than one-third of participants lost 20% or more of their initial body weight—outcomes previously only achievable through bariatric surgery.

By contrast, the SUSTAIN trials evaluating Ozempic at diabetes-approved doses (0.5mg to 1mg weekly) showed average weight reductions of 4.5kg to 6.5kg—clinically meaningful but substantially less than the 15.3kg average seen with Wegovy's higher dose [1][3]. This dose-dependent relationship underscores why proper licensing and appropriate dosing matter for weight management outcomes.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) regularly advises patients that whilst both formulations can influence appetite and satiety through the same GLP-1 mechanism, only Wegovy provides the dosing schedule specifically studied and approved for obesity treatment in the UK.

What the Trials Tell Us About Safety

Both medications share a similar side effect profile, predominantly gastrointestinal symptoms including nausea, diarrhoea, and constipation [2][3]. These effects typically diminish over the dose escalation period. The STEP trials' comprehensive safety monitoring at higher semaglutide doses found no unexpected safety signals, supporting Wegovy's regulatory approval for long-term weight management.

Serious adverse events were rare in both trial programmes, occurring in fewer than 10% of participants. However, semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2]. All patients require thorough clinical assessment before starting either medication.

Why Patients Consider Switching from Ozempic to Wegovy

Many UK patients initially prescribed Ozempic off-label for weight loss are now transitioning to Wegovy for several compelling reasons. First, using a medication within its licensed indication provides better regulatory protection and ensures prescribers can access the full clinical guidance developed specifically for weight management rather than diabetes care.

Second, the supply situation has stabilised considerably. During 2022-2023, global shortages of both medications led to widespread access issues. As manufacturing capacity has expanded, Wegovy availability has improved across UK pharmacies, making legitimate weight loss treatment more accessible than relying on diabetes medications diverted from their intended patient population.

Third, transparent pricing structures at pharmacies like Cured Pharmacy have made Wegovy increasingly cost-competitive. At £79.00 for Wegovy compared to variable pricing for off-label Ozempic use, patients often find the properly licensed option represents better value whilst ensuring they receive treatment designed specifically for their clinical needs.

The Switching Process: What to Expect

Transitioning from Ozempic to Wegovy requires clinical oversight from a UK prescriber. If you're currently on Ozempic 1mg weekly, your prescriber will typically recommend starting Wegovy at the 1.7mg dose rather than beginning the full escalation schedule from 0.25mg [2]. This approach maintains therapeutic effect whilst minimising the risk of gastrointestinal side effects.

Your UK-registered prescriber will review your current response, assess any side effects you've experienced, and determine the most appropriate transition protocol. Some patients may benefit from a brief overlap period or dose adjustment based on their individual tolerance and weight loss progress to date.

Wegovy Dosing Schedule and What to Expect

Wegovy follows a carefully designed dose escalation schedule that allows your body to adapt to increasing semaglutide levels over 16-20 weeks. You'll begin with 0.25mg weekly for four weeks, then progress through 0.5mg, 1mg, and 1.7mg doses, each maintained for four weeks, before reaching the maintenance dose of 2.4mg weekly [2].

This gradual escalation significantly reduces the incidence and severity of gastrointestinal side effects compared to starting at higher doses. Clinical trial data shows that approximately 74% of patients successfully reach and maintain the 2.4mg dose, with most discontinuations occurring in the first 20 weeks during escalation [2].

Each Wegovy pen is pre-filled and designed for once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. The injection process takes less than a minute, and most patients report minimal discomfort. Comprehensive injection training is provided as part of your treatment package, and our clinical team remains available throughout your treatment journey.

Cost Comparison: Ozempic vs Wegovy UK Pricing

Understanding the true cost of semaglutide treatment requires looking beyond headline prices. When Ozempic is prescribed off-label for weight loss, patients often face inconsistent pricing, limited prescriber support, and potential supply interruptions as diabetes patients—the medication's intended recipients—take priority during shortages.

Wegovy pricing at Cured Pharmacy starts from £79.00 per month, representing a £10 saving compared to standard market rates. This transparent pricing includes your medication, UK prescriber consultation, and discreet home delivery. Unlike some providers who advertise low prices but add consultation fees, prescription charges, or delivery costs, our upfront pricing means you know exactly what you'll pay before beginning your clinical assessment.

When comparing costs, consider the complete treatment pathway. Wegovy's licensed status means you receive treatment specifically designed for weight management, with dosing schedules and clinical monitoring protocols developed through dedicated obesity trials rather than adapted from diabetes care. This often translates to better outcomes and more appropriate clinical support throughout your weight loss journey.

Hidden Costs of Off-Label Prescribing

Off-label use of Ozempic for weight loss may seem economical initially, but patients often encounter unexpected costs. These can include more frequent prescriber consultations as clinicians navigate dosing outside licensed guidelines, potential insurance complications if adverse events occur during off-label use, and supply disruptions requiring emergency switches to alternative treatments.

By choosing Wegovy—the medication specifically licensed and studied for your condition—you benefit from established clinical pathways, comprehensive safety data at appropriate doses, and regulatory oversight designed to protect patients using semaglutide for weight management.

Getting Started with Wegovy at Cured Pharmacy

Beginning your weight loss journey with Wegovy at Cured Pharmacy takes less than three minutes through our online clinical assessment. Our UK-registered prescribers will review your medical history, current medications, weight loss goals, and any contraindications to ensure semaglutide treatment is safe and appropriate for you.

All prescription medications, including Wegovy, require clinical assessment by a UK prescriber before they can be dispensed. This isn't merely a regulatory formality—it's essential patient safety practice. Your prescriber will assess factors including your BMI, weight-related health conditions, previous weight loss attempts, and any medications that might interact with semaglutide [2].

Once approved, your Wegovy prescription is dispensed by our GPhC-registered pharmacy (registration number 9012511) and delivered in discreet, unbranded packaging directly to your door. You'll receive comprehensive guidance on injection technique, dose escalation timing, and managing potential side effects. Our clinical team remains available throughout your treatment for any questions or concerns that arise.

As a UK-registered online pharmacy, we supply only genuine, UK-licensed medicines sourced through legitimate pharmaceutical supply chains. Every Wegovy pen you receive carries full regulatory approval from the MHRA and comes with patient information leaflets in English, ensuring you have access to complete safety information and usage instructions.

Scientific References

1. Sorli, C., Harashima, S. I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology, 5(4), 251-260. https://doi.org/10.1016/S2213-8587(17)30013-X
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
3. Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. The Lancet Diabetes & Endocrinology, 5(5), 341-354. https://doi.org/10.1016/S2213-8587(17)30092-X

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is indicated for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. Individual results may vary. Treatment outcomes depend on multiple factors including adherence, lifestyle modifications, and individual metabolic response.